Aksoy Asude, Artas Gokhan, Sevindik Omur Gokmen
Asude Aksoy, Department of Medical Oncology, Medical Faculty, Firat University, Elazig, Turkey.
Gokhan Artas, Department of Pathology, Medical Faculty, Firat University, Elazig, Turkey.
Pak J Med Sci. 2017 May-Jun;33(3):560-565. doi: 10.12669/pjms.333.12559.
Several pathways are known to be activated during metastasis and treatment of cancer. We investigated the role of osteopontin (OPN) and stathmin-1 (STHMN1) in metastatic castrate-resistant (mCRPC).
We included 30 patients who received at least 6 cycles of taxane regimen for metastatic mPC in the present study. For this study retrospective data was taken from Firat University, Faculty of Medicine, Medical Oncology Department between 2009 and 2015. OPN expression and STHMN1 expression were retrospectively evaluated by immunohistochemical staining in biopsy specimens. The relationship between the expression levels of OPN and STMN1 and the response to taxane based regimen and survival was analyzed.
There was mild or strong overexpression of OPN and STHMN1 in all the patients. STHMN1 expression was mildly positive (+2) in four of the cases (13.2%) while it was strongly positive (+3) in 25 (83.4%) cases. Similarly, OPN expression was mildly positive (+2) and strongly positive (+3) in five (16.6%) and 25 (87.4%) patients, respectively. There was no significant correlation between the expression levels of STHMN1 and OPN, survival, and response to taxane based regimen (p>0.05); however, OPN overexpression showed a significant correlation with lower Gleason scores (GS) (p:0.032).
STHMN1 and OPN may be prognostic markers although they are not predictive markers of response to treatment in mCRPC. The overexpression of OPN may help identifying patients with lower GS.
已知多种途径在癌症转移和治疗过程中被激活。我们研究了骨桥蛋白（OPN）和14-3-3σ蛋白（STHMN1）在转移性去势抵抗性前列腺癌（mCRPC）中的作用。
本研究纳入了30例接受至少6个周期紫杉烷方案治疗转移性mPC的患者。本研究的回顾性数据取自2009年至2015年间菲拉特大学医学院医学肿瘤学系。通过免疫组织化学染色对活检标本中的OPN表达和STHMN1表达进行回顾性评估。分析OPN和STMN1表达水平与基于紫杉烷方案的反应和生存之间的关系。
所有患者中均存在OPN和STHMN1的轻度或强过表达。STHMN1表达在4例（13.2%）病例中为轻度阳性（+2），而在25例（83.4%）病例中为强阳性（+3）。同样，OPN表达在5例（16.6%）和25例（87.4%）患者中分别为轻度阳性（+2）和强阳性（+3）。STHMN1和OPN的表达水平、生存以及对基于紫杉烷方案的反应之间无显著相关性（p>0.05）；然而，OPN过表达与较低的Gleason评分（GS）显著相关（p：0.用32）。
STHMN1和OPN可能是预后标志物，尽管它们不是mCRPC治疗反应的预测标志物。OPN的过表达可能有助于识别GS较低的患者。
